Merck (MRK) Announces Upcoming Presentation of Strong ZEPATIER Data in Certain HCV Genotypes
Tweet Send to a Friend
Merck (NYSE: MRK) announced results from multiple analyses at The Liver Meeting® 2016, which provide additional evidence supporting the use ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
